Genomic Biomarkers Assess Treatment Prognosis in Blood Cancers
By LabMedica International staff writers Posted on 04 Aug 2014 |
Image: The GeneRead DNAseq Targeted Panels V2 kit (Photo courtesy of Qiagen).
B Image: Bone marrow aspirate smear from a patient with myelodysplastic syndromes (Photo courtesy of Dr. Robert P Hasserjian, MD).
The biomarker gene, splicing factor 3B subunit 1(SF3B1), is believed to play a critical role in the prognosis of patients with myelodysplastic syndromes (MDS), a group of hematological cancers in which bone marrow does not produce enough healthy blood cells.
Mutations of this gene, which is an important component of the spliceosome machinery, indicate a more favorable disease progression for patients than the "wild-type" gene, so testing for these gene variants could potentially provide important guidance for treatment based on a personalized healthcare approach to MDS.
QIAGEN N.V. (Hilden, Germany) announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo (Japan). QIAGEN licensed the SF3B1 biomarker in an ongoing expansion of the oncohematology offering for clinical research and diagnostics. Three additional spliceosome biomarkers implicated in various blood cancers and targeting variants in the U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1,U2AF35), the zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2 (ZRSR2) and the serine/arginine-rich splicing factor 2 (SFRS2) genes are also part of the license agreement.
Those genes are included in QIAGEN's GeneRead DNAseq Leukemia V2 gene panel for next-generation sequencing (NGS), which has been launched earlier this month together with 13 other new cancer gene panels that are compatible with any NGS sequencer and customizable to include other genes or gene regions of clinical or biological interest. The GeneRead technology provides the most cost-effective and time-efficient approach for target enrichment of assay panels for NGS. The panels use as little as 10 nanograms of starting DNA material per pool, require only three hours to enrich for targets and substantially reduce the time to go from isolated DNA sample to sequencing-ready libraries. They are compatible for use with formalin-fixed, paraffin-embedded (FFPE) samples, do not require specialized instruments, and achieve industry leading coverage of greater than 96% of coding regions, a specificity greater than 90% of reads on target and a greater than 90% uniformity of bases covered by at least 20% of the mean coverage depth.
Vincent Fert, MSc, QIAGEN's Personalized Healthcare Program Leader, said, “Building on a broad portfolio of molecular diagnostics for blood cancers, QIAGEN continues to partner with clinical researchers at pharmaceutical companies and academic centers to extend the benefits of personalized healthcare. Because several Pharma companies are developing potential anticancer drugs targeting the SF3B1 gene, this biomarker also holds potential for co-development as a companion diagnostic.”
Related Links:
QIAGEN N.V.
University of Tokyo
Mutations of this gene, which is an important component of the spliceosome machinery, indicate a more favorable disease progression for patients than the "wild-type" gene, so testing for these gene variants could potentially provide important guidance for treatment based on a personalized healthcare approach to MDS.
QIAGEN N.V. (Hilden, Germany) announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo (Japan). QIAGEN licensed the SF3B1 biomarker in an ongoing expansion of the oncohematology offering for clinical research and diagnostics. Three additional spliceosome biomarkers implicated in various blood cancers and targeting variants in the U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1,U2AF35), the zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2 (ZRSR2) and the serine/arginine-rich splicing factor 2 (SFRS2) genes are also part of the license agreement.
Those genes are included in QIAGEN's GeneRead DNAseq Leukemia V2 gene panel for next-generation sequencing (NGS), which has been launched earlier this month together with 13 other new cancer gene panels that are compatible with any NGS sequencer and customizable to include other genes or gene regions of clinical or biological interest. The GeneRead technology provides the most cost-effective and time-efficient approach for target enrichment of assay panels for NGS. The panels use as little as 10 nanograms of starting DNA material per pool, require only three hours to enrich for targets and substantially reduce the time to go from isolated DNA sample to sequencing-ready libraries. They are compatible for use with formalin-fixed, paraffin-embedded (FFPE) samples, do not require specialized instruments, and achieve industry leading coverage of greater than 96% of coding regions, a specificity greater than 90% of reads on target and a greater than 90% uniformity of bases covered by at least 20% of the mean coverage depth.
Vincent Fert, MSc, QIAGEN's Personalized Healthcare Program Leader, said, “Building on a broad portfolio of molecular diagnostics for blood cancers, QIAGEN continues to partner with clinical researchers at pharmaceutical companies and academic centers to extend the benefits of personalized healthcare. Because several Pharma companies are developing potential anticancer drugs targeting the SF3B1 gene, this biomarker also holds potential for co-development as a companion diagnostic.”
Related Links:
QIAGEN N.V.
University of Tokyo
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans